The anticoagulant effect of Bothrops castelnaudi snake venom (Castelnaud's pit viper)

Clinical and Evolutionary Implications of Dynamic Coagulotoxicity Divergences in Bothrops (Lancehead Pit Viper) Venoms

Despite coagulotoxicity being a primary weapon for prey capture by Bothrops species (lancehead pit vipers) and coagulopathy being a major lethal clinical effect, a genus-wide comparison has not been undertaken. To fill this knowledge gap, we used thromboelastography to compare 37 venoms, from across the full range of geography, taxonomy, and ecology, for their action upon whole plasma and isolated fibrinogen. Potent procoagulant toxicity was shown to be the main venom effect of most of the species tested. However, the most basal species (B. pictus) was strongly anticoagulant; this is consistent with procoagulant toxicity being a novel trait that evolved within Bothrops subsequent to their split from anticoagulant American pit vipers. Intriguingly, two of the arboreal species studied (B. bilineatus and B. taeniatus) lacked procoagulant venom, suggesting differential evolutionary selection pressures. Notably, some terrestrial species have secondarily lost the procoagulant venom trait: the Mogi Mirim, Brazil locality of B. alternatus; San Andres, Mexico locality of B. asper; B. diporus; and the São Roque of B. jararaca. Direct action on fibrinogen was extremely variable; this is consistent with previous hypotheses regarding it being evolutionary decoupled due to procoagulant toxicity being the primary prey-capture weapon. However, human patients live long enough for fibrinogen depletion to be clinically significant. The extreme variability may be reflective of antivenom variability, with these results thereby providing a foundation for such future work of clinical relevance. Similarly, the venom diversification trends relative to ecological niche will also be useful for integration with natural history data, to reconstruct the evolutionary pressures shaping the venoms of these fascinating snakes.

First report of an accident with the speckled forest pit viper (Bothriopsis taeniata) in Brazil

The first reported case of an accident with Bothriopsis taeniata in Brazil is described. The victim, a 43-year-old man, was bitten just above his right heel and presented a clinical condition compatible with mild Bothrops poisoning: local edema with hemorrhage at the bite site and pain, although without coagulopathy.

A non-toxic anticoagulant metalloprotease: purification and characterization from Indian cobra (Naja naja naja) venom

A non-toxic potent anticoagulant metalloprotease NN-PF(3) has been purified to homogeneity from the Indian cobra (Naja naja naja) venom through a combination of column chromatography and electrophoresis. NN-PF(3) is a single chain protein with a molecular weight of 68 kDa by SDS-PAGE. It hydrolysed casein, gelatin, haemoglobin and bovine fibrinogen, but did not hydrolyse bovine serum albumin or synthetic substrates such as TAME, BAEE and BAPNA. EDTA, EGTA and cyanide inhibited the enzymatic activity while 1,10-phenanthroline, PMSF, leupetin and pepstatin did not show any effect. NN-PF(3) is a metalloprotease containing Ca(2+) and Zn(2+) at a molar ratio of 1:1.2 and 1:0.4, respectively, as revealed by atomic absorption spectroscopy. NN-PF(3) was non-lethal up to an i.p. dose of 15 mg/kg body weight of mice and is devoid of myotoxicity, cytotoxicity and haemorrhagic activity. It is weakly oedematic, but strongly anticoagulant in property and the effect observed was both dose and time dependent.

Coagulant and anticoagulant activities of Bothrops lanceolatus (Fer de lance) venom

Bothrops lanceolatus venom contains caseinolytic, phospholipase, esterase and haemorrhagic activities. We have investigated the coagulant and anticoagulant actions of B. lanceolatus venom on human citrated plasma and on purified plasma components. Although B. lanceolatus venom up to 50 microg/ml was unable to clot citrated plasma, at concentrations > or = 5 microg/ml the venom dose-dependently clotted purified human fibrinogen, indicating the presence of a thrombin-like enzyme. Human plasma (final concentration > or = 12.5%) dose-dependently inhibited the venom-induced fibrinogen clotting. This finding suggested that endogenous plasma protease inhibitors can affect the venom's action on fibrinogen. To investigate this possibility, B. lanceolatus venom was incubated with different plasma protease inhibitors and the activity on fibrinogen tested. alpha(2)-Macroglobulin and alpha(1)-antitrypsin did not interfere with the coagulant activity of the venom whereas the antithrombin-III/heparin complex partially inhibited this activity. A non-toxic, acidic phospholipase A(2) purified from B. lanceolatus venom prolonged the activated partial thromboplastin time in human plasma from 39.7+/-0.5 s (control with saline) to 60.2+/-0.9 s with 50 microg of PLA(2) (p<0.001), suggesting an anticoagulant activity associated with this enzyme. This anticoagulant activity may account for some of the effects of the venom on blood coagulation.

Isolation and purification of superbins I and II from Austrelaps superbus (copperhead) snake venom and their anticoagulant and antiplatelet effects

Two proteins with anticoagulant and antiplatelet activities were purified from Austrelaps superbus (copperhead) venom by gel filtration, ion-exchange and reverse-phase chromatographic methods. These purified proteins were designated superbins I and II. Superbin I was homogeneous, as indicated by electrospray ionization-mass spectrometry, with a mol. wt of 13,252.3 +/- 1.6, whereas superbin II contained two closely related proteins of mol. wts 13,235.5 +/- 1.1 and 13,212.9 +/- 1.2. Both superbins showed phospholipase A2 activity and exhibited weak anticoagulant effects when tested by one-step prothrombin time clotting assays. The 'dissection approach' was used to identify the coagulation complex(es) inhibited by these enzymes in the extrinsic coagulation cascade. The results indicate that both the enzymes inhibit the extrinsic tenase complex, but not the prothrombinase complex, similarly to other weakly anticoagulant phospholipases. Superbins I and II also inhibited aggregation of human platelets induced by collagen.

Haemostatic changes caused by the venoms of South American snakes

Changes in the haemostatic mechanism caused by venoms of Bothrops, Crotalus and Lachesis snakes from Central and South America in human accidents are reviewed. Changes in the blood coagulation mechanism could be found depending on the action of the venom on clotting factors.

Mechanism of the anticoagulant, Cerastase F-4, isolated from Cerastes cerastes (Egyptian sand viper) venom

An anticoagulant enzyme, Cerastase F-4, from the venom of Cerastes cerastes was purified to homogeneity and was characterized (1). In the present report the mode of its fibrinogenolytic and fibrinolytic actions, and its effects on some other blood coagulation factors are described. Cerastes F-4 was shown to readily hydrolyze the alpha A chain of fibrinogen followed by the hydrolysis of the beta B chain. The gamma-chain was relatively resistant to hydrolysis. It also degrades the three chains of fibrin at different rates. The degradation products of the two substrates shown on SDS-polyacrylamide gel were quite different from those produced by plasmin, indicating different sites of cleavage by the enzyme. Using specific chromogenic substrates, Cerastase F-4 seems not to show thrombin-like, plasmin-like, kallikrein-like, antithrombin, or antiplasmin actions. Also, it does not activate prothrombin or plasminogen but degrades both of them slowly. It is concluded that the anticoagulation property of the purified enzyme, Cerastase F-4, is due to its destruction of fibrinogen.